A Step in the Journey of Denosumab From Bone-Targeted Therapy to Seed- and Soil-Targeted Therapy
Authors:
- 1 April 2009
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (10) , 1534-1536
Abstract
No abstract availableThis publication has 26 references indexed in Scilit:
- Randomized Phase II Trial of Denosumab in Patients With Bone Metastases From Prostate Cancer, Breast Cancer, or Other Neoplasms After Intravenous BisphosphonatesJournal of Clinical Oncology, 2009
- Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directionsCancer Treatment Reviews, 2008
- Randomized Trial of Denosumab in Patients Receiving Adjuvant Aromatase Inhibitors for Nonmetastatic Breast CancerJournal of Clinical Oncology, 2008
- Extended Efficacy and Safety of Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate TherapyClinical Cancer Research, 2008
- Influence of RANKL inhibition on immune system in the treatment of bone diseasesJoint Bone Spine, 2008
- Randomized Active-Controlled Phase II Study of Denosumab Efficacy and Safety in Patients With Breast Cancer-Related Bone MetastasesJournal of Clinical Oncology, 2007
- Denosumab in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2006
- Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic AcidJournal of Clinical Oncology, 2005
- Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid TumorsJNCI: Journal of the National Cancer Institute, 2005
- Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligandProceedings of the National Academy of Sciences, 1999